<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01339676</url>
  </required_header>
  <id_info>
    <org_study_id>2007-001958-99</org_study_id>
    <secondary_id>EudraCT 2007-001958-99</secondary_id>
    <nct_id>NCT01339676</nct_id>
  </id_info>
  <brief_title>Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)</brief_title>
  <official_title>Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turku</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, double blind, randomised, placebo controlled, parallel group, phase 4
      pilot study investigating colecalciferol (vitamin D3) as an add-on treatment to
      subcutaneously administered interferon-beta-1b in relapsing-remitting multiple sclerosis
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure: the proportion of patients with P-PTH&lt; 20 ng/l and S-OH(D)2 &gt; 85 nmol/l at 6 and 12 months</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Gadolinium-enhancing lesions on T1 and /or new enlarging lesions on Measure: T2/PD based on MRI done 12 months following randomisation compared with the MRI done at the time of randomisation</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identically appearing once weekly peroral capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colecalciferol</intervention_name>
    <description>Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>Identically appearing once weekly peroral placebo capsules</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 to 55 years

          -  remitting-relapsing multiple sclerosis according to McDonald criteria who fulfill the
             reimbursement criteria for interferon-beta and have used interferon-beta-1b for at
             least one month

          -  EDSS (expanded disability statsu scale) ≤ 5

          -  no neutralising antibodies to INFB as measured by indirect MxA test

          -  prepared and considered to follow the protocol

          -  using appropriate contraceptive methods (women of childbearing potential)

          -  has given informed consent

        Exclusion Criteria:

          -  serum calcium &gt;2.6 mmol/L

          -  serum 25(OH)D2 (kalsidiol) &gt; 85 nmol/L

          -  presence of primary hyperparathyroidism (serum intact PTH, parathyroid hormone)&gt;65
             ng/L)

          -  pregnancy or unwillingness to use contraception

          -  alcohol or drug abuse

          -  use of glucocorticoid treatment other than intravenous methylprednisolone for
             treatment of relapses

          -  current use of other immunomodulatory therapy than interferon-beta-1b

          -  known allergy to cholecalciferol or arachis oil (peanuts)

          -  therapy with digitalis, calcitonin or active vitamin D3 analogues during the previous
             12 months or multivitamins containing vitamin D during previous two weeks preceding
             study entry

          -  any condition predisposing to hypercalcaemia (such as any type of cancer)

          -  sarcoidosis

          -  nephrolithiasis or renal insufficiency, serum creatinine above 1.5 times the normal
             upper reference limit

          -  significant hypertension (Blood Pressure &lt;180/110 mmHg)

          -  hyperthyroidism, or hypothyroidism in the year before the study began

          -  a history of nephrolithiasis during the previous five years

          -  cardiac insufficiency or significant cardiac dysrhythmia

          -  unstable or advanced ischaemic heart disease

          -  has suffered a major depression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>FIN-20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>April 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2011</study_first_posted>
  <last_update_submitted>May 18, 2011</last_update_submitted>
  <last_update_submitted_qc>May 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Merja Soilu-Hanninen, MD, PhD, docent, neurologist</name_title>
    <organization>University of Turku, Department of Neurology, Turku, Finland</organization>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>MRI</keyword>
  <keyword>Randomised Trial</keyword>
  <keyword>Finland</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

